1. Pink Sheet

Should Obese Patients Be Included In Every Drug Development Program?

 
• By Brenda Sandburg

FDA officials question whether modeling tools can predict which drugs have different disposition in obese populations. They say physiologically-based pharmacokinetic data cannot be used as a surrogate for actual clinical trial data at this time.

Obese patient
Experts consider how obese patients should be included in drug development studies • Source: Shutterstock

Experts from the US Food and Drug Administration, academia and industry did not reach a consensus on whether obese patients should be considered a specific population in new drug development studies but they agreed that they should be included in trials and that modeling tools might provide insights on whether a compound’s dosing and disposition is different in obese patients.

Panelists discussed how to bridge drug efficacy and safety to obese patients at a virtual workshop convened by the FDA...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

New UK Network Targets Speed And Inclusion For Commercial Clinical Trials

 
• By Vibha Sharma

The UK government expects that its new nation-wide network will enable companies to set up clinical trials more quickly and expand access to diverse patient populations across the National Health Service.

Oncology: Plan Ahead To Rule Out Harm When Survival Not The Endpoint, US FDA Says

 
• By Michael McCaughan

The FDA recommended sponsors plan ahead for potential issues if overall survival is not feasible as a primary or secondary efficacy endpoint in clinical trials and must be analyzed as a safety outcome.

Selective Safety Data Collection In Clinical Trials: Adoption Lags Despite Benefits, US FDA Says

 
• By Manas Mishra

Lack of awareness is limiting use of guidelines that simplify safety reporting for some late-stage trials, FDA says, while also highlighting wins. Boehringer experienced mixed results, while Novartis, Lilly, and Merck were more successful, and Roche should have probably tried, white paper suggests.